Literature DB >> 25087645

Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.

Wendy Chen1, Gil Binenbaum2, Karen Karp3, Agnieshka Baumritter3, Denise J Pearson4, Albert M Maguire4, Graham E Quinn4.   

Abstract

An infant of 36 weeks' postmenstrual age (PMA) and 25 weeks' gestation received bilateral intravitreal bevacizumab injections for type 1 retinopathy of prematurity. He underwent laser photocoagulation in both eyes 5 days later, confluent except for 1 clock hour obscured by hemorrhage in the left eye. Despite initial regression, neovascularization in both vascularized and lasered retina with plus disease recurred, requiring repeat laser bilaterally at 51 weeks' PMA and vitrectomy in the left eye at 54 weeks' PMA. Whereas late recurrence is thought to occur rarely after laser treatment, infants who have received both bevacizumab injections and laser may still require long-term surveillance for recurrence. In this case, fundus photography proved valuable for appreciating recurrent plus disease because the initial treatments had resulted in marked retinal vessel attenuation.
Copyright © 2014 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25087645      PMCID: PMC4277745          DOI: 10.1016/j.jaapos.2014.03.011

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  10 in total

1.  Reactivation of retinopathy of prematurity after bevacizumab injection.

Authors:  Jennifer Hu; Michael P Blair; Michael J Shapiro; Steven J Lichtenstein; John M Galasso; Rashmi Kapur
Journal:  Arch Ophthalmol       Date:  2012-08

2.  Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.

Authors:  B J Lee; J H Kim; H Heo; Y S Yu
Journal:  Eye (Lond)       Date:  2012-06-15       Impact factor: 3.775

3.  Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab.

Authors:  Hamid Hosseini; Mohammad Reza Razeghinejad
Journal:  J Neuroophthalmol       Date:  2009-06       Impact factor: 3.042

4.  Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

Authors:  Wei-Chi Wu; Po-Ting Yeh; San-Ni Chen; Chung-May Yang; Chi-Chun Lai; Hsi-Kung Kuo
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

Review 5.  Screening examination of premature infants for retinopathy of prematurity.

Authors:  Walter M Fierson
Journal:  Pediatrics       Date:  2012-12-31       Impact factor: 7.124

6.  Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye.

Authors:  Ulrich Schraermeyer; Sylvie Julien
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-22       Impact factor: 3.117

7.  Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).

Authors:  Paola Dorta; Andrés Kychenthal
Journal:  Retina       Date:  2010-04       Impact factor: 4.256

8.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

9.  Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: is there an association?

Authors:  Ali A Bodla; Prasad Rao
Journal:  Indian J Ophthalmol       Date:  2010 Jul-Aug       Impact factor: 1.848

10.  Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5.

Authors:  Subhadra Jalali; Divya Balakrishnan; Zarifa Zeynalova; Tapas Ranjan Padhi; Padmaja Kumari Rani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-12-25       Impact factor: 5.747

  10 in total
  6 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

3.  Smouldering retinopathy of prematurity: a case treated by multiple antivascular endothelial growth factor therapy.

Authors:  Divya Balakrishnan; Vikas Ambiya; Subhadra Jalali; Padmaja Kumari Rani
Journal:  BMJ Case Rep       Date:  2016-08-29

Review 4.  [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].

Authors:  T U Krohne; A Müller; P P Larsen; F G Holz
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

Review 5.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

6.  Fzd4 Haploinsufficiency Delays Retinal Revascularization in the Mouse Model of Oxygen Induced Retinopathy.

Authors:  Michael H Ngo; Joanna Borowska-Fielding; Godfrey Heathcote; Sara Nejat; Melanie E Kelly; Christopher R McMaster; Johane M Robitaille
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.